Anzeige
Mehr »
Dienstag, 25.11.2025 - Börsentäglich über 12.000 News
Goldrausch 2.0: 60% Insideranteil - warum dieser Gold-Explorer als Geheimtipp gilt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MZH8 | ISIN: AU000000ACW3 | Ticker-Symbol: 3AC
Tradegate
25.11.25 | 17:42
0,039 Euro
+16,67 % +0,006
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
ACTINOGEN MEDICAL LIMITED Chart 1 Jahr
5-Tage-Chart
ACTINOGEN MEDICAL LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
0,0340,04023:01
0,0360,03920:34

Aktuelle News zur ACTINOGEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ACTINOGEN Aktie jetzt für 0€ handeln
MiCanaccord Genuity initiates coverage on Actinogen Medical stock with Spec. Buy14
MiACTINOGEN MEDICAL LIMITED: Application for quotation of securities - ACW2
MiACTINOGEN MEDICAL LIMITED: Results of Annual General Meeting1
18.11.ACTINOGEN MEDICAL LIMITED: ACW CEO & CFO present at Bell Potter Healthcare Conference-
18.11.ACTINOGEN MEDICAL LIMITED: Actinogen 2025 AGM Chairs address and CEOs presentation1
13.11.Actinogen Medical - XanaMIA passes first safety milestone262Actinogen Medical reported that the independent Data Monitoring Committee (DMC) of the company's pivotal Phase IIb/III XanaMIA study in patients with mild-to-moderate Alzheimer's disease (AD) has met...
► Artikel lesen
12.11.ACTINOGEN MEDICAL LIMITED: ACW positive XanaMIA Data Monitoring Committee meeting4
05.11.ACTINOGEN MEDICAL LIMITED: Application for quotation of securities - ACW11
02.11.ACTINOGEN MEDICAL LIMITED: ACW presents at BIO-Europe partnering conference in Vienna2
27.10.ACTINOGEN MEDICAL LIMITED: ACW progress update and Q&A webinar today5
24.10.Actinogen Medical - XanaMIA recruitment exceeds expectations282Actinogen Medical reported that, due to recent accelerations in screening and enrolment for its Phase IIb/III XanaMIA study of lead candidate Xanamem in patients with mild-to-moderate Alzheimer's disease...
► Artikel lesen
23.10.ACTINOGEN MEDICAL LIMITED: Advance notice ACW progress update and Q&A webinar11
23.10.ACTINOGEN MEDICAL LIMITED: ACW September 2025 quarterly activity report & Appendix 4C1
20.10.ACTINOGEN MEDICAL LIMITED: ACW CEO presents at Canaccord Drug & Device Conference-
20.10.ACTINOGEN MEDICAL LIMITED: ACW confirms eligibility for further $1.9m RDTI-
20.10.ACTINOGEN MEDICAL LIMITED: ACW achieves early screening closure for XanaMIA trial1
15.10.ACTINOGEN MEDICAL LIMITED: Annual Report to Shareholders14
15.10.ACTINOGEN MEDICAL LIMITED: Letter to Shareholders, Notice of AGM & Proxy Form-
14.10.ACTINOGEN MEDICAL LIMITED: ACW receives initial $5.5m R&D tax incentive rebate2
29.09.ACTINOGEN MEDICAL LIMITED: Notification of cessation of securities - ACW2
Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1